XML 23 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows
$ in Millions
 12 Months Ended
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Operating activities:      
Net income (loss) $ (2,472) $ (16,449) $ 311
Adjustments to reconcile net income to net cash provided by operations:      
Impairment of long-lived assets 5,621 20,882 1,645
Depreciation and amortization 1,842 2,112 1,524
Net change in operating assets and liabilities (1,823) (1,645) (116)
Deferred income taxes-net and uncertain tax positions (837) (2,331) 15
Stock-based compensation 155 133 124
Other items (135) 13 (14)
Research and development in process 114 175 422
Net loss from sale of long-lived assets and investments (19) (1,090) (764)
Venezuela deconsolidation loss   383  
Venezuela impairment of net monetary assets   42 603
Other-than-temporary impairment     140
Net cash provided by operating activities 2,446 2,225 3,890
Investing activities:      
Beneficial interest collected in exchange for securitized trade receivables 1,735 1,282 1,335
Proceeds from sales of long-lived assets and investments 890 3,477 2,002
Purchases of property, plant and equipment (651) (874) (901)
Purchases of investments and other assets (119) (200) (481)
Other investing activities 11 (282) (212)
Acquisitions of businesses, net of cash acquired   43 (36,148)
Net cash provided by (used in) investing activities 1,866 3,446 (34,405)
Financing activities:      
Repayment of senior notes and loans and other long-term liabilities (7,446) (3,300) (999)
Proceeds from senior notes and loans, net of issuance costs 4,434 506 25,252
Net change in short-term debt (260) (1,683) 1,998
Other financing activities (57) (74) (169)
Dividends paid on ordinary shares (12) [1] (901) [1] (1,303) [1]
Dividends paid on preferred shares (10) [1] (260) [1] (255) [1]
Proceeds from exercise of options by employees [2] [2] 35
Dividends paid to non-controlling interests   (38)  
Proceeds from issuance of ordinary shares, net of issuance costs     329
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs     329
Net cash provided by (used in) financing activities (3,351) (5,750) 25,217
Translation adjustment on cash and cash equivalents (142) 54 (660)
Net change in cash and cash equivalents 819 (25) (5,958)
Balance of cash and cash equivalents at beginning of year 963 988 6,946
Balance of cash and cash equivalents at end of year 1,782 963 988
Non-cash financing and investing activities:      
Beneficial interest obtained in exchange for securitized trade receivables 1,716 1,295 1,365
Conversion of mandatory convertible preferred shares into ordinary shares 3,880    
Share issuance to Allergan plc for the Actavis Generics acquisition     5,065
Shares transferred to Takeda as part of the establishment of Teva Takeda     1,825
Actavis Generics contingent consideration     302
Interest 815 795 290
Income taxes, net of refunds 420 106 341
Net change in operating assets and liabilities:      
Other current assets (1,437) 658 (517)
Trade payables, accrued expenses, employee-related obligations and other current liabilities (500) (3,083) (695)
Trade receivables net of sales reserves and allowances 88 514 343
Inventories 26 199 370
Inventory step-up   67 383
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information $ (1,823) $ (1,645) $ (116)
[1] In 2018, the amounts consist of tax withholding payments made on dividends paid in 2017.
[2] Represent an amount less than 0.5 million